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Oral cancer risk and vitamin D status, intake and 
 supplementation: A reviewK Kingsley1*, C Bergman2, M Keiserman3, C Mobley1
Abstract
Introduction
Vitamin D sufficiency is associated with a variety of human health ben-
efits, while vitamin D deficiency has 
been identified as a potential risk fac-
tor for several health-related issues, 
including oral cancer. The goal of this 
critical review was to assess the re-
search, epidemiologic evidence and 
mechanisms through which vitamin 
D may influence oral cancer risk or 
progression.
Discussion
Recent evidence now suggests that 
vitamin D exhibits several differ-
ent effects on normal and cancer-
ous cells, including up-regulation of 
anti-proliferation and proapoptotic 
factors, as well as inhibition of cell-
cycle promoters and growth factor 
signalling pathways, such as Wnt and 
mitogen-activated protein kinase 
(MAPK). Some studies, however, 
have demonstrated inconclusive re-
sults, which may be complicated by 
inadequate study design to account 
for baseline vitamin D status or defi-
ciencies, and also by tumour-specific 
up-regulation of the vitamin D catab-
olism enzyme, cytochrome p450 24 
(CYP24), or mutations in the vitamin 
D receptor (VDR), which have been 
observed in some oral cancers.
Conclusion
This comprehensive analysis of re-
search regarding vitamin D status, 
intake and metabolism suggests oral 
cancer risk may, in fact, be more in-
terconnected than previously ac-
knowledged. Furthermore, more 
in-depth analysis of VDR and CYP24 
expression, along with baseline vita-
min D status, may elucidate some of 
the underlying mechanisms of oral 
cancer responsiveness, which may be 
useful to oral oncologists, oral health 
care providers and oral epidemiolo-
gists as they strive to improve patient 
health and outcomes.
Introduction
Oral cancer
Although the rates of oral cancer inci-
dence and mortality have declined in 
the United States and other industri-
alized countries over recent decades, 
concomitant increases have been 
observed in other nations and world-
wide, in general1,2. As workplace par-
ticipation and social mobility have 
increased along with disposable in-
comes in developing economies, the 
availability of tobacco and alcohol 
products has been associated with 
increasing rates of oral cancers2–5. 
Studies of the primary risk factors 
for the development of oral cancers 
in the United States have found that 
tobacco use and, to a lesser extent, al-
cohol consumption, when combined, 
may be responsible for as much as 
80% of this cancer risk2,4,6. 
However, these studies have also 
uncovered differing incidence and 
mortality rates among demographic 
subgroups within the population, 
including stark differences by age, 
sharp increases observed among 
females and much higher rates ob-
served among minorities7–13. An ad-
ditional important risk factor for oral 
and pharyngeal cancers (OPCs) is oral 
infection with the human papilloma-virus (HPV)1,11. Oral HPV infection 
may be disproportionately associated 
with specific demographic subgroups, 
such as men and some  minority sub-
groups, which may underlie some 
of the divergent geospatial and geo-
graphic OPC trends observed12,14.
Dietary influences
Although the majority of OPC risk in 
developed countries may be attrib-
utable to tobacco and alcohol con-
sumption or HPV infection, several 
studies have recently demonstrated 
that opposing, health-protective ef-
fects and reduced incidence of OCP 
may be associated with intake of 
specific dietary components such as 
coffee, fibre, folic acid and the vita-
mins A, C, D and E15,16. In fact, recent 
meta-analyses have demonstrated 
consistent, inverse associations be-
tween the intake of specific dietary 
components, such as folate, and the 
risk, development and progression 
of OCP17,18. In addition, dietary limi-
tations or restrictions and micronu-
trient deficiencies have been shown 
to increase OCP risk15–17. It is difficult 
(and often problematic) to distin-
guish the effects of specific micro-
nutrients or constituents in dietary 
 intake studies from those of the foods 
that contain them16. This may explain 
why researchers have concluded that 
dietary intake (but not specific vita-
mins or micronutrients) accounts for 
as much as 20–25% of the variability 
in OCP risk15,16.
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Discussion
The authors have referenced some 
of their own studies in this review. 
These referenced studies have been 
conducted in accordance with the 
Declaration of Helsinki (1964), and 
the protocols of these studies have 
been approved by the relevant ethics 
committees related to the institution 
in which they were performed. All 
human subjects, in these referenced 
studies, gave informed consent to 
participate in these studies.
The primary mechanism of vitamin 
D action is mediated through binding 
of either 1,25(OH)2D3 (active form) or 
25(OH)D (less active form) to the VDR, 
which is a member of the nuclear re-
ceptor superfamily of steroid and thy-
roid hormones with gene-regulatory 
and consequent anti-proliferative 
properties30,34. Binding of 1,25(OH)2D 
to the VDR (either in the cell nucleus 
or in the cytoplasm) promotes as-
sociation of the VDR–1,25(OH)2D 
complex with the retinoid X recep-
tor (RXR)21,30. The 1,25(OH)2D–
VDR–RXR complex binds to vitamin 
D-response elements in DNA which 
operate to initiate gene transcription. 
Activation of the VDR by 1,25(OH)2D 
can restore or enhance proapop-
totic effects in different cancer cells 
through transcriptional activation of 
bax and p-calpain, two effective proa-
poptotic proteins35,36. VDR–vitamin D 
activation also been demonstrated to 
increase mRNA expression of trans-
forming growth factor, a potent anti-
proliferative cytokine in normal and 
early stage cancer cells; superoxide 
dismutase, which may reduce oxida-
tive stress-induced DNA damage and 
loss to DNA repair mechanisms that 
contribute to carcinogenesis and in-
flammatory cytokine production; 
as well as cyclin-dependent kinase 
(CDK) inhibitor p21, RBL2, RBLP6 
and forkhead box O (FOXO) tumour 
suppressors that function to counter-
act MAPK-mediated phosphorylation 
and growth35,37–39.
VDR activation may also facilitate 
transcriptional repression of Bc1-2 
1,25(OH)2D, is between 38 and 
144 pmol/l (16 and 60 pg/ml) that 
has a circulation half-life between 4 
and 6 hours30,31. Vitamin D doses may 
also be stated in international units 
(IU), which adjusts for biological ac-
tivity or effect with one IU of vitamin 
D defined as the activity of 0.025 μg 
of 1,25(OH)2D329. The simplest way 
to understand and compare the vary-
ing studies of vitamin D may be to 
apply the conversion of IU to grams 
of 1,25(OH)2D3; 40 IU equals 1 μg 
in dietary sources, and to apply the 
conversion of clinical serum levels to in vitro concentrations, 2.5nmol/l 
equals 1 ng/ml30.   Although vitamin D is routinely 
supplemented into dietary food 
staples of developed countries, the 
primary determinant of vitamin D 
status for the developing world is 
sun exposure, since vitamin D pro-
duction in the skin is proportional 
to ultraviolet (UV) light exposure32. 
For instance, although an eight ounce 
glass of milk in the United States is 
fortified to contain 100 IU of vitamin 
D, exposure of the skin to enough 
UV-B radiation to cause a slight pink-
ness in Caucasian skin produces the 
equivalent to an oral dose of 20,000 
IU of vitamin D20,32. These findings 
may explain the epidemiologic ob-
servations that increased sun expo-
sure in certain geographic regions 
and among certain populations was 
associated with reduced cancer mor-
tality and risk at all tumour sites. 
Data from more than 100 countries 
have demonstrated strong, inverse 
correlations between solar UVB ex-
posure for 15 types of cancer and sig-
nificant (although less robust) effects 
observed among nine other cancers, 
including those of the larynx and oral 
cavity/pharynx19–22,32,33.  
Based upon this information, the 
primary objective of this study is 
to provide a critical review of not 
only the research and epidemio-
logic evidence but also the mecha-
nisms through which vitamin D may 
 influence OPC risk and progression.
Vitamin D
Large-scale population studies have 
revealed that low serum vitamin D 
levels are associated with significant 
increases in cancer risk19,20. More 
specifically, epidemiologic and case-
controlled studies have now dem-
onstrated that low vitamin D levels 
are strongly associated with OPC 
risk21,22. In fact, more recent evidence 
now demonstrates that OPC patients 
are more likely to harbour vitamin 
D receptor (VDR) gene polymor-
phisms, mutations or deletions23–25. 
Conversely, those with specific VDR 
mutations were at higher risk for de-
veloping OPC than those with normal 
genotypes26–28.Vitamin D3 precursors are pro-
duced in the skin upon exposure to 
sunlight, but also may be ingested 
from dietary sources, such as ani-
mal food products, while vitamin D2 may be obtained from plant-
based products and synthetically 
manufactured dietary additives or 
nutritional supplements29,30. No sig-
nificant differences between the 
metabolism of the major circulat-ing forms, vitamin D2 [25(OH)D2] 
and vitamin D3 [25(OH)D3] have been 
noted, with vitamin D precursors ei-
ther from sun exposure or from diet 
hydroxylated in the liver via the p450 
27A system to 25-hydroxyvitamin D 
[25(OH)D]30. The circulating concen-
tration of 25(OH)D ranges between 
20 and 150 nmol/l (9 and 60 ng/ml), 
which has a normal serum half-life of 
about 3 weeks, with vitamin D intoxi-
cation described at concentrations 
above 375 nmol/l (150 ng/ml)31.
Although the primary site for vi-
tamin D metabolism is hydroxyla-
tion in the hepatic p450 27A system, 
the kidney, bones and parathyroid 
gland are major sites of additional 
processing of 25(OH)D to the ac-
tive form 1,25- dihydroxy vitamin 
D [1,25(OH)2D] via the p450 27B 
system, which is also involved in 
both calcium and phosphorous ho-meostasis30,31. The normal human 
serum range for the active form, 
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 modulate the risk or progression of 
OPC. Although many clinical studies 
have suggested vitamin D status, in-
take and supplementation may have 
a significant influence on oral can-
cer risk, progression and mortality, 
growing epidemiologic evidence now 
suggests that dietary supplementa-
tion may not provide levels similar 
to UVB exposure. As work environ-
ments in the developing world are 
increasing indoors and the obesity 
crisis further limits physical activity 
and outdoor exposure, the impact 
and influence of vitamin D intake 
may become increasingly critical. In 
addition, although many studies have 
demonstrated the anti-tumour ef-
fects of vitamin D both in vitro and in 
vivo, new evidence suggests these ef-
fects are modulated by other factors, 
including tissue and tumour regula-
tion of CYP24. These data combined 
suggest that more research is needed to examine the in vitro effects of vi-
tamin D on OCP which include analy-
ses of CYP27 and CYP24 activity and 
VDR expression, while clinical and 
in vivo studies should more closely 
examine the relationship between 
baseline vitamin D status and allevi-
ating deficiency, achieving adequacy. 
This information may be useful to 
oral oncologists, oral health care pro-
viders and oral epidemiologists as 
they strive to improve patient health 
and outcomes.
Abbreviations list
CDK, cyclin-dependent kinase; FOXO, 
forkhead box O; HPV, human papil-
lomavirus; IU, international unit; 
MAPK, mitogen-activated protein 
kinase; OPC, oral and pharyngeal 
cancer; RXR, retinoid X receptor; 
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